全文获取类型
收费全文 | 183079篇 |
免费 | 17491篇 |
国内免费 | 8065篇 |
专业分类
耳鼻咽喉 | 2419篇 |
儿科学 | 3988篇 |
妇产科学 | 2478篇 |
基础医学 | 31960篇 |
口腔科学 | 5762篇 |
临床医学 | 14915篇 |
内科学 | 23545篇 |
皮肤病学 | 4517篇 |
神经病学 | 9997篇 |
特种医学 | 4448篇 |
外国民族医学 | 118篇 |
外科学 | 15710篇 |
综合类 | 29039篇 |
现状与发展 | 48篇 |
一般理论 | 5篇 |
预防医学 | 7088篇 |
眼科学 | 3611篇 |
药学 | 14974篇 |
85篇 | |
中国医学 | 6836篇 |
肿瘤学 | 27092篇 |
出版年
2024年 | 180篇 |
2023年 | 2685篇 |
2022年 | 3563篇 |
2021年 | 6502篇 |
2020年 | 6243篇 |
2019年 | 5864篇 |
2018年 | 6097篇 |
2017年 | 6450篇 |
2016年 | 6775篇 |
2015年 | 7596篇 |
2014年 | 11465篇 |
2013年 | 12769篇 |
2012年 | 10992篇 |
2011年 | 12097篇 |
2010年 | 9885篇 |
2009年 | 9404篇 |
2008年 | 9872篇 |
2007年 | 9938篇 |
2006年 | 9005篇 |
2005年 | 8152篇 |
2004年 | 7199篇 |
2003年 | 6198篇 |
2002年 | 5053篇 |
2001年 | 4332篇 |
2000年 | 3561篇 |
1999年 | 3109篇 |
1998年 | 2532篇 |
1997年 | 2493篇 |
1996年 | 2143篇 |
1995年 | 2166篇 |
1994年 | 1925篇 |
1993年 | 1590篇 |
1992年 | 1309篇 |
1991年 | 1227篇 |
1990年 | 954篇 |
1989年 | 895篇 |
1988年 | 837篇 |
1987年 | 688篇 |
1986年 | 618篇 |
1985年 | 798篇 |
1984年 | 713篇 |
1983年 | 498篇 |
1982年 | 533篇 |
1981年 | 420篇 |
1980年 | 357篇 |
1979年 | 277篇 |
1978年 | 186篇 |
1977年 | 153篇 |
1976年 | 122篇 |
1975年 | 47篇 |
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
991.
992.
《European journal of surgical oncology》2020,46(6):1111-1117
BackgroundSquamous cell carcinoma (SCC) of the rectum is a rare form of gastrointestinal malignancy. The current knowledge on the natural history is primarily derived from case series.MethodsUsing the National Cancer Data Base (NCDB), we determined the prognostic factors and overall survival (OS) outcomes of rectal SCC reported to NCDB between 2004 and 2015. Kaplan-Meier method and log-rank test were used to perform OS analysis. Propensity matched analysis was undertaken to compare the OS outcomes between rectal and anal SCC.ResultsOf the 3405 cases included in our analysis, 67% were female. Median age at diagnosis was 61 years and did not differ by sex. In stages I-III, patients who received definitive chemoradiation only (108 months) had a better median OS as compared to surgery alone (76 months) (p = 0.012). On multivariate analysis, age <60 years, female sex, and receipt of chemoradiation with or without surgery were independent predictors of better OS in stage I-III disease. Administration of chemoradiation was associated with better OS in stage IV disease. On propensity matched analysis comparing outcomes to anal SCC, OS of rectal SCC was inferior (79 months) to anal SCC (113 months) (p < 0.001), no such difference in OS was noted in the cohorts that received surgery plus post-surgical chemoradiation (p = 0.12).ConclusionOutcomes of rectal SCC were dependent upon age, sex, comorbidity score, and therapy received. Chemoradiation alone or in combination with surgery was associated with a better median OS in patients with stages I-III. 相似文献
993.
《European journal of surgical oncology》2020,46(6):1046-1051
BackgroundThe purpose of this article is to illuminate differences in published clinical practice guideline recommendations for breast reconstruction after prophylactic and therapeutic mastectomy.MethodsTen guidelines were identified through a systematic search of websites and databases of reputable oncology guideline developers, and key differences and gaps in recommendations were noted. Quality assessment of the guidelines was conducted by three reviewers using the AGREE II tool, focusing on breast reconstruction specific documents rather than the general breast cancer guidelines.ResultsThe most comprehensive guidelines were published by Alberta Health Services, Cancer Care Ontario, the American Society of Plastic Surgeons, and the Association of Breast Surgery/British Association of Plastic Reconstructive and Aesthetic Surgeons. AGREE II scores in the domains of “Scope and Purpose” and “Clarity and Presentation” were ranked relatively high for all four guidelines while “Applicability” and “Editorial Independence” were ranked relatively low. The Alberta and Ontario guidelines were the overall highest ranked guidelines across all domains.ConclusionOverall, these guidelines provide consistent recommendations on who should receive breast reconstruction education, who is a candidate for postmastectomy breast reconstruction, and the appropriate timing of reconstruction and extent of mastectomy. Future updates from all should focus on expanding to include alloplastic and autologous forms of reconstruction and should include a broad scope of relevant questions. 相似文献
994.
《药学学报(英文版)》2020,10(4):667-679
Combination therapy has shown its promise in the clinic for enhancing the efficacy of tumor treatment. However, the dose control of multiple drugs and their non-overlapping toxicity from different drugs are still great challenge. In this work, a single model drug, paclitaxel (PTX), is used to realize combination therapy and solve the problems mentioned above. Either PTX or its triphenylphosphine derivative (TPTX) is encapsulated in galactose-modified liposomes (GLips) to obtain GLips-P or GLips-TP, which are simply mixed in different ratios to finely control the proportion of PTX and TPTX. These mixed liposomes, GLips-P/TP, feature a cascade target delivery of PTX, from tissue to cell, and then to organelle. PTX plays a primary role to cause the cytotoxicity by microtubule bindings in cytoplasm, while TPTX is proved to increase the intracellular levels of caspase-3 and caspase-9 that cause apoptosis via a mitochondria-mediated pathway. Notably, GLips-P/TP 3:1 exhibited the significant drug synergy in both cytotoxicity assay of HepG2 cells and the treatment efficacy in Heps xenograft ICR mouse models. This work not only demonstrates the great promise of a cascade targeting delivery for precise tumor treatment, but also offers a novel platform to design combinatory therapy systems using a single drug. 相似文献
995.
《药学学报(英文版)》2020,10(7):1294-1308
A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds with therapeutic advantages over single target inhibitors and drug combinations. Inspired by our previous efforts in designing antitumor evodiamine derivatives, herein selective histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) dual inhibitors were successfully identified, which showed potent in vitro and in vivo antitumor potency. Particularly, compound 30a was orally active and possessed excellent in vivo antitumor activity in the HCT116 xenograft model (TGI = 75.2%, 150 mg/kg, p.o.) without significant toxicity, which was more potent than HDAC inhibitor vorinostat, TOP inhibitor evodiamine and their combination. Taken together, this study highlights the therapeutic advantages of evodiamine-based HDAC1/TOP2 dual inhibitors and provides valuable leads for the development of novel multi-targeting antitumor agents. 相似文献
996.
目的 探究SCLC基因调控机制,为寻找SCLC早期诊断及靶向治疗潜在的生物标志物提供依据。方法 采用生物信息学方法从公共基因芯片数据库获取小细胞肺癌(SCLC)mRNA数据并筛选出差异表达基因(DEGs),对DEGs进行基因本体(GO)和基因组百科全书数据库(KEGG)富集分析,构建蛋白互作网络,筛选出核心基因并利用Kaplan-Meier在线工具进行生存分析。结果 17例SCLC组织样本和19例正常肺组织样本中筛选出248个DEGs,包括172个高表达基因和76个低表达基因(P<0.05)。GO和KEGG富集分析结果显示,DEGs的功能主要涉及细胞周期、DNA复制、错配修复、P53信号通路等,蛋白互作分析网络筛选出6个节点度最高的核心基因:TOP2A、PCNA、RFC4、 FEN1、CCNA2和MCM2,并与患者预后相关。结论 DEGs涉及的分子功能和信号通路可能是SCLC发生的分子机制,而核心基因可能是治疗SCLC的潜在靶点。 相似文献
997.
998.
999.
《Clinical genitourinary cancer》2020,18(1):56-61
BackgroundClear-cell renal cell carcinoma (ccRCC) is one of the most common malignancies in humans and is usually associated with poor outcomes. Cancers are considered to be genetic diseases. Therefore, a better understanding of genetic alterations that are related to disease progression or poor prognosis can help to more precisely identify high-risk patients and treat them more effectively. The aim of this study was to examine the frequency of whole chromosome 9 loss (monosomy of chromosome 9) and its prognostic value in patients with ccRCC.Materials and MethodsSingle nucleotide polymorphism-based chromosome microarray (CMA) analysis was performed on 103 resected specimens from patients with ccRCC who had undergone partial or radical nephrectomy between January 2002 and March 2017 at Fox Chase Cancer Center. Monosomy 9 was correlated with clinicopathologic parameters and recurrence-free survival.ResultsChromosome 9 loss was detected in 31 (30%) of 103 tumors. Tumors with chromosome 9 loss had higher histologic grade (3 and 4; P < .001) and pathologic stage (P < .001). In 59 patients with non-metastatic ccRCC, chromosome 9 loss was also associated with higher recurrence rate and shorter recurrence-free survival (RFS) (12-month RFS, 77.8%; 95% confidence interval, 36.5%-93.9% for chromosome 9 loss vs. 95.7%; 95% confidence interval, 84.0%-98.9% for no loss; P = .002).ConclusionsChromosome 9 loss was found in 30% of patients with ccRCC and correlated with higher grade, advanced stage, and shorter RFS in patients with Stage I to III ccRCC. 相似文献
1000.
目的:检测可手术非小细胞肺癌患者术前血浆中VEGF、sVEGFR-1的表达水平,并分析其与临床病理资料和长期生存的关系。方法:收集98例可手术非小细胞肺癌患者术前静脉血,用ELISA方法检测血浆中VEGF和sVEGFR-1的表达水平,并分析其表达水平与患者临床病理资料和长期生存之间的关系。结果:可手术非小细胞肺癌患者术前血浆中VEGF、sVEGFR-1的表达水平与患者的临床病理资料没有相关性,但是多因素生存分析中,年龄、TNM分期和VEGF/sVEGFR-1比值是可手术非小细胞肺癌患者长期生存的独立预后因子。结论:血浆VEGF/sVEGFR-1比值与可手术非小细胞肺癌患者的长期生存相关,该比值在非小细胞肺癌的意义值得进一步深入研究。 相似文献